These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8788487)

  • 1. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent.
    Nichols DE; Monte A; Huang X; Marona-Lewicka D
    Behav Brain Res; 1996; 73(1-2):117-9. PubMed ID: 8788487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.
    Monte AP; Marona-Lewicka D; Kanthasamy A; Sanders-Bush E; Nichols DE
    J Med Chem; 1995 Mar; 38(6):958-66. PubMed ID: 7699712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity.
    Pertz HH; Milhahn H; Eich E
    J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane.
    Oberlender R; Pfaff RC; Johnson MP; Huang XM; Nichols DE
    J Med Chem; 1992 Jan; 35(2):203-11. PubMed ID: 1732537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of 1,2,4-substituted piperazines, new serotonin receptor ligands, with 5-HT1A and 5-HT2A receptors.
    Chilmonczyk Z; Cybulski M; Iskra-Jopa J; Chojnacka-Wójcik E; Tatarczyńska E; Kłodzińska A; Leś A; Bronowska A; Sylte I
    Farmaco; 2002 Apr; 57(4):285-301. PubMed ID: 11989808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of serotonin (5-HT) receptor agonists, partial agonists and antagonists at cloned human 5-HT1A receptors that are negatively coupled to adenylate cyclase in permanently transfected HeLa cells.
    Pauwels PJ; Van Gompel P; Leysen JE
    Biochem Pharmacol; 1993 Jan; 45(2):375-83. PubMed ID: 8382063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats.
    Popik P; Krawczyk M; Kuziak A; Bugno R; Hogendorf A; Staroń J; Nikiforuk A
    J Psychopharmacol; 2019 Nov; 33(11):1447-1455. PubMed ID: 31452444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors.
    Krebs-Thomson K; Paulus MP; Geyer MA
    Neuropsychopharmacology; 1998 May; 18(5):339-51. PubMed ID: 9536447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP).
    Callahan PM; Cunningham KA
    Eur J Pharmacol; 1994 May; 257(1-2):27-38. PubMed ID: 8082704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats.
    Kleven MS; Assié MB; Koek W
    J Pharmacol Exp Ther; 1997 Aug; 282(2):747-59. PubMed ID: 9262338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common mechanism for lysergic acid, indolealkylamine and phenethylamine hallucinogens: serotonergic medication of behavioral effects in rats.
    Sloviter RS; Drust EG; Damiano BP; Connor JD
    J Pharmacol Exp Ther; 1980 Aug; 214(2):231-8. PubMed ID: 6104720
    [No Abstract]   [Full Text] [Related]  

  • 13. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).
    Brandt SD; Kavanagh PV; Twamley B; Westphal F; Elliott SP; Wallach J; Stratford A; Klein LM; McCorvy JD; Nichols DE; Halberstadt AL
    Drug Test Anal; 2018 Feb; 10(2):310-322. PubMed ID: 28585392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).
    Nichols DE; Frescas S; Marona-Lewicka D; Kurrasch-Orbaugh DM
    J Med Chem; 2002 Sep; 45(19):4344-9. PubMed ID: 12213075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
    Arvanov VL; Liang X; Russo A; Wang RY
    Eur J Neurosci; 1999 Sep; 11(9):3064-72. PubMed ID: 10510170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of novel aryloxyalkylimidazolines on rat 5-HT2A and 5-HT2C receptors.
    Siegel BW; Freedman J; Vaal MJ; Baron BM
    Eur J Pharmacol; 1996 Feb; 296(3):307-18. PubMed ID: 8904083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the 5-HT
    Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX
    J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Displacement of specific serotonin and lysergic acid diethylamide binding by Ergalgin, a new antiserotonin drug.
    Oelszner W
    Acta Biol Med Ger; 1980; 39(8-9):897-901. PubMed ID: 7282219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.